PMID: 16614539Apr 15, 2006Paper

Safety of high-dose naltrexone treatment: hepatic transaminase profiles among outpatients

Clinical Neuropharmacology
Suck Won KimRory P Remmel

Abstract

This study was carried out to test the hypothesis that the hepatic safety profile of prolonged high-dose oral naltrexone (150 mg/d) is acceptable if over-the-counter analgesic use is restricted. Data from 41 consecutive outpatients with impulse-control disorder receiving naltrexone therapy were analyzed. The mean treatment duration was 328 days and the mean naltrexone dose was 142 mg/d. Pretherapy/posttherapy mean aspartate transaminase and alanine transaminase levels in the naltrexone-alone group were 21.79/22.54 and 21.74/21.49 U, respectively (all within reference range). Although limited in scope, these findings support the hypothesis that long-term use of high-dose oral naltrexone is safe in otherwise healthy patients with impulse-control disorders who restrict their intake of acetaminophen, aspirin, or nonaspirin nonsteroidal anti-inflammatory drugs (NSAID). However, confirming studies are needed.

References

Jan 1, 1987·Biological Psychiatry·J E MitchellD Pfohl
Sep 1, 1994·Journal of Clinical Pharmacology·D S SaxA Kim
Sep 13, 2001·International Clinical Psychopharmacology·S W Kim, J E Grant
Jan 5, 2002·Journal of Clinical Psychopharmacology·S W KimR P Remmel
May 10, 2002·The Journal of Clinical Psychiatry·Jon E Grant, Suck Won Kim

❮ Previous
Next ❯

Citations

Feb 16, 2010·Journal of Addictive Diseases·Einat PelesMiriam Adelson
Jan 25, 2007·Primary Care Companion to the Journal of Clinical Psychiatry·Pinhas N DannonMoshe Kotler
Jan 23, 2016·Expert Opinion on Pharmacotherapy·Marcelo Piquet-Pessôa, Leonardo F Fontenelle
Feb 5, 2008·Alcoholism, Clinical and Experimental Research·Michael R LuceyCharles P O'Brien
Apr 17, 2012·International Journal of Endocrinology·Mehmet GunduzMesut Ozkaya
Mar 30, 2016·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Julia M A SinclairDavid S Baldwin
Dec 22, 2006·Expert Review of Neurotherapeutics·Katherine LowengrubPinhas N Dannon
Jan 29, 2011·Annals of the New York Academy of Sciences·David R Gastfriend
Aug 26, 2014·Pharmacological Reports : PR·Krzysztof ŁabuzekBogusław Okopień
Jan 16, 2008·CNS Drugs·Iulian IancuPinhas N Dannon
Jul 30, 2011·Alcoholism, Clinical and Experimental Research·Jeanette M TetraultUNKNOWN Veterans Aging Cohort Study Team
Apr 6, 2016·Clinical Neuropharmacology·Gihyun YoonJoseph Westermeyer
Oct 18, 2007·Expert Review of Neurotherapeutics·Paolo MannelliAshwin A Patkar

❮ Previous
Next ❯

Related Concepts

Related Feeds

Addiction

This feed focuses mechanisms underlying addiction and addictive behaviour including heroin and opium dependence, alcohol intoxication, gambling, and tobacco addiction.

Related Papers

The Journal of Clinical Psychiatry
Jon E Grant, Suck Won Kim
The International Journal of Eating Disorders
James MitchellStephen Wonderlich
Current Drug Targets. CNS and Neurological Disorders
J E MitchellJ L Roerig
© 2022 Meta ULC. All rights reserved